Evaluation on Thrombotic Events Frequency in JAK2 V617F Positive Patients

RM Freitas1*, FC Guia2, LM Nascimento2, A Atalla1, A E Hallak1, MO Santos1 and CMC Maranduba2
1Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
2Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil

Keywords: Polycythemia vera; JAK2 V617F; Thrombotic events

Introduction

The Polycythemia Vera (PV) is a myeloproliferative neoplasia which comes from a change in the multipotent hematopoietic stem cells that causes the accumulation of erythrocytes, leukocytes and morphologically normal platelets independent of erythropoietin. It can bring about leukocytosis, thrombocytosis, splenomegaly and an increased risk of thrombotic events. Around 95% of the patients diagnosed with PV have the JAK2 V617F mutation [1]. Even in the absence of thrombotic events, the patients with a type of myeloproliferative neoplasia (MPN) present a hypercoagulable state which can be identified for an increasing in the concentration of several plasmatic markers on the system of haemostatic activation [2].

Besides this studies suggest that these patients with MPN who have the JAK2 V617F mutation are exposed to an increasing risk of thrombotic complications possibly because of the increased platelet and the leukocyte activation [3].

Material and Methods

There were 31 patients with PV diagnoses were selected according to the established criteria by WHO (2008) between March and September, 2013. Considering this total number five patients refused to participate in the research. The project was approved by the Human Research Ethics Committee of University Hospital. The PCR-AE technique was performed according to standard conditions and the product of PCR was visualized on 2% Agarose gel [4]. On the negative samples to the presence of the JAK2 V617F mutation automatic sequencing was done with the aim of identifying possible changes in the exon 12 in the JAK2 gene. All the DNA samples were genotyped for the JAK2 V617F mutation (NM-004972) and with a normal control that was included in each run.

Discussion

The frequency of thrombosis in patients with PV varies from 19% to 39% as we can see in Table 1. With this data, we emphasize the role of the research about this mutation on the investigation about the causes of thrombotic events especially in unusual site highlighting the MPN as a cause of thrombophilia. This probably occurs due to correlation of the mutation presence and the increase of platelets and leukocytes and with the hypercoagulable state [3].

<table>
<thead>
<tr>
<th>Publications</th>
<th>Patients with PV</th>
<th>Occurrence of thrombotic events (%)</th>
<th>Arterial Thrombosis (%)</th>
<th>Venous Thrombosis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Passamonti et al.</td>
<td>163</td>
<td>34%</td>
<td>64%</td>
<td>36%</td>
</tr>
<tr>
<td>Barbui and Finazzi</td>
<td>1638</td>
<td>38.60%</td>
<td>75%</td>
<td>25%</td>
</tr>
</tbody>
</table>

Abstract

The Polycythemia Vera is a myeloproliferative neoplasia whose overall incidence is 0.7-2.6 cases per 100,000 inhabitants/year. 92.3% of the patients were positive to the JAK2 V617F mutation (exon 14) and 7.7% were negative also to the mutations on the exon 12. Around 29.16% of the JAK2 V617F positive patients had arterial or venous thrombosis. The percentage of patients with the JAK2 V617F mutation and the frequency of thrombosis in PV JAK2 positive patients demonstrated in our study are according to the data presented in the literature.

Copyright: © 2017 Freitas RM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Passamonti et al. 70 24.30% 70.60% 29.40%
Marchiolli 1638 38.60% - -
Coucelo et al. 31 39% 75% 25%
Alvarez-Larrán et al. 163 23% - -
Edahiro et al. 66 19% - -

Table 1: Scientific data about the relation between the number of patients with PV and the occurrence of thrombotic events associated with the disease.

Funding
This project was supported by CAPES.

References